Forecasting Pneumonitis Associated with Immune Checkpoint Inhibitors in Lung Cancer: Creation and Assessment of Various Machine Learning Models - Takeaways - MDSpire

Forecasting Pneumonitis Associated with Immune Checkpoint Inhibitors in Lung Cancer: Creation and Assessment of Various Machine Learning Models

  • By

  • Yuxin Li

  • Yang Ji

  • Chunxiao Wang

  • Chunhui Qin

  • Kang Yu

  • Ling Liu

  • Jiahui Chen

  • Wei Meng

  • Tong Zhang

  • February 20, 2026

  • 0 min

Share

  • 1

    Lung cancer is a leading cause of death, with immune-checkpoint inhibitors significantly improving treatment outcomes but also causing serious side effects.

  • 2

    CIP, a severe immune-related adverse event, can lead to respiratory symptoms and is a major cause of mortality among patients receiving ICIs.

  • 3

    The incidence of CIP varies, reported between 3%-5% in clinical trials and 7%-19% in real-world studies, highlighting its clinical significance.

  • 4

    Predictive models for CIP risk have been developed, but many rely on single feature selection methods, limiting their effectiveness.

  • 5

    This study aims to identify predictors of CIP and develop multiple noninvasive risk prediction models for lung cancer patients undergoing immunotherapy.

Original Source(s)

Forecasting Pneumonitis Associated with Immune Checkpoint Inhibitors in Lung Cancer: Creation and Assessment of Various Machine Learning Models

  • by Yuxin Li, Yang Ji, Chunxiao Wang, Chunhui Qin, Kang Yu, Ling Liu, Jiahui Chen, Wei Meng, Tong Zhang

  • February 20, 2026

Related Content

Severe IL-6–dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report

Zapnometinib treatment and influenza A virus infection modulate the HLA class I ligandome in human lung adenocarcinoma cells

An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy